Company Overview of Urigen Pharmaceuticals, Inc.
Urigen Pharmaceuticals, Inc., a development stage company, engages in the development and commercialization of therapeutic products for patients with urological disorders in North America. Its clinical stage product includes URG101, a bladder instillation for bladder pain syndrome/intersticial cystitis for men and women. The company is based in Wilmington, Delaware.
501 Silverside Road
Wilmington, DE 19809
Key Executives for Urigen Pharmaceuticals, Inc.
Chief Executive Officer and Director
Scientific Founder, Chief Medical Officer, Director and Member of Scientific Advisory Board
Co-Founder and IP Counsel
Vice President of Finance & Operations and Director
Compensation as of Fiscal Year 2014.
Urigen Pharmaceuticals, Inc. Key Developments
Imprimis Pharmaceuticals, Inc. Enters into License Agreement with Urigen Pharmaceuticals, Inc. for Patented Urology Formulation
Oct 29 14
Imprimis Pharmaceuticals, Inc. announced that it has entered into a license agreement, under which Imprimis acquired the US rights to commercially compound a patented combination of alkalized lidocaine and heparin from Urigen Pharmaceuticals, Inc. Physicians in the US and abroad have been prescribing and instilling this compounded drug formulation in different dosages to treat individual patients suffering from interstitial cystitis, also known as painful bladder syndrome (IC/PBS). Under the terms of the agreement, Imprimis shall pay Urigen tiered royalties based on net product sales with a minimum annual payment per unit for each prescription dispensed. The license does not require any cash payment by Imprimis upon execution. The license is non-exclusive for a period of six months, at which time Imprimis has the sole right to convert to an exclusive license. Once converted to an exclusive license, Imprimis is obligated to make certain annual minimum payments. The license is for the US market only and covers certain US patent rights that extend through 2026. The agreement contains provisions for the parties to remain long-term partners throughout the product lifecycle.
Urigen Pharmaceuticals Raises $750,000 Debt Financing
Jul 23 13
Urigen Pharmaceuticals raised $750,000 in a debt financing, according to documents filed with the Securities & Exchange Commission. The Wilmington, Del., specialty pharmaceutical company specializes in the developing products for patients with urological ailments such as painful bladder syndrome, urethritis, nocturia and over active bladder. Urigen's lead new drug candidate, the experimental painful bladder syndrome treatment URG101, is a proprietary combination of approved drugs that is instilled into the bladder. The company was seeking to raise $1 million.
Similar Private Companies By Industry
Recent Private Companies Transactions
May 27, 2014
Most Searched Private Companies
Sponsored Financial Commentaries